Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430975 · ClinicalTrials.gov registry record
Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites
A clinical trial of Radiation Exposure, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- 72
- Enrollment target
- 1
- Study location
NCT01430975 is a study of Radiation Exposure that has completed, run by Bracco Diagnostics. The registered enrollment target is 72 participants, above the 40-participant average among 7 other Radiation Exposure trials with a reported enrollment target (80% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01430975, a study of Radiation Exposure, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to be performed at two clinical sites where patients received CardioGen-82 during the time period January to June, 2011 and where patients were scanned chronologically near to the index patients (2 days before or after). Of these, it is planned that at least 30 patients will be entered in this trial. Index patient is the term applied to individuals who had radiation spectra indicative of Sr-82 and Sr-85 detected by hand-held survey meters.
Conditions Studied
Interventions
- DRUG CardioGen-82
Study Locations (1)
New Jersey
- Bracco Diagnostics, Inc. - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01430975
The ClinicalTrials.gov registry entry for NCT01430975 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 40-participant average among 7 other Radiation Exposure trials with a reported enrollment target (80% higher). The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Radiation Exposure appearing as the primary indexed condition, and to 1 intervention - of which CardioGen-82 is the first listed.
NCT01430975 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT01430975 about?
NCT01430975 is a clinical study titled "Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites". This study is to be performed at two clinical sites where patients received CardioGen-82 during the time period January to June, 2011 and where patients were scanned chronologically near to the index patients (2 days before or after). Of these, it is planned that at least 30 patients will be entered...
What is the current status of trial NCT01430975?
This trial is currently completed. The enrollment target is 72 participants. The study started on 2011-09. Estimated completion is 2012-03.
What conditions does trial NCT01430975 study?
This clinical trial studies the following conditions: Radiation Exposure.
What interventions are being tested in trial NCT01430975?
The interventions under investigation include: CardioGen-82 (DRUG).
Who is sponsoring clinical trial NCT01430975?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01430975 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiation Exposure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
RECRUITING · NA
-
MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets
RECRUITING
-
Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead Placement
RECRUITING · NA
-
Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Reduce Radiation Exposure in Fluoroscopic Interventions Evaluation
COMPLETED · NA
-
A Prospective Study of Radiation Exposure to Surgeons
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.